Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review
Akihiro Orita, Daichi Hoshina, Kuninori Hirosaki
Abstract
We report a case of pyoderma gangrenosum (PG) caused by secukinumab, which was successfully treated with risankizumab. We also reviewed reported cases of PG caused by interleukin (IL)-17 inhibitors. The clinical course of this case indicates that IL-23 may play an important role in the pathogenesis of PG and therefore IL-23-targeting therapies may be a treatment option for PG.
Topics & Concepts
SecukinumabPyoderma gangrenosumMedicineInterleukin 23DermatologyPathogenesisPyodermaMonoclonalImmunologyInterleukin 17Internal medicineMonoclonal antibodyPsoriasisCytokineAntibodyDiseasePsoriatic arthritisAutoimmune and Inflammatory DisordersOral Health Pathology and TreatmentHidradenitis Suppurativa and Treatments